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Asian Ethnicity Is a Favorable Prognostic Factor for Overall
Survival in Non-small Cell Lung Cancer (NSCLC) and Is
Independent of Smoking Status
Sai-Hong Ignatius Ou, MD, PhD,*†‡ Argyrios Ziogas, PhD,†‡ and Jason A. Zell, DO, MPH*†‡
Background: We previously showed that Asian ethnicity was an
independent favorable prognostic factor in non-small cell lung
cancer (NSCLC). Many Asian NSCLC patients were never-smok-
ers, and never-smokers had improved survival than ever-smokers.
We investigated whether Asian ethnicity is a favorable prognostic
factor independent of smoking status.
Methods: Retrospective population-based study of NSCLC cases
from the cancer surveillance programs of three Southern California
counties from 1991 to 2005.
Results: A total of 20,140 NSCLC patients with known smoking
status were analyzed of which 9.1% were never-smokers and 6.5%
were Asians. There was a threefold increase in the percentage of
Asian never-smokers as compared with ever-smokers. Asians had
the highest overall survival (OS) among the 4 major ethnicities (p
0.0001) and never-smokers had improved OS over ever-smokers
(p 0.0183) by univariate analyses. By multivariate analyses, Asian
ethnicity was an independent and favorable prognostic factor for OS
(versus non-Asian; hazard ratio [HR]  0.861, 95% confidence
interval [CI]: 0.808–0.918, p  0.0001), among smokers (versus
non-Asian; HR  0.867, 95% CI: 0.807–0.931, p  0.0001), and
among never-smokers (versus non-Asian; HR  0.841, 95% CI:
0.728–0.971, p  0.0180). Never-smoker was a favorable prognos-
tic factor if ethnicity was not accounted for (versus ever-smoker;
HR  0.936, 95% CI: 0.886–0.988, p  0.0169) but was no longer
an independent favorable prognostic factor (versus ever-smoker;
HR 0.953, 95% CI: 0.902–1.007, p 0.0861) after accounting for
ethnicity.
Conclusions: Asian ethnicity is an independent favorable prognos-
tic factor for OS in NSCLC regardless of smoking status.
Key Words: Never-smoker, Prognostic factors, Asian ethnicity,
Hispanic ethnicity, epidemiology, Non-small cell lung cancer, Cal-
ifornia Cancer Registry.
(J Thorac Oncol. 2009;4: 1083–1093)
Lung cancer is the number one cancer cause of death in theworld. Most of lung cancer is caused by exposure to
tobacco smoke. However, lung cancer in never-smokers con-
stitutes the seventh most common cause of cancer deaths
worldwide.1 Recently lung cancer in never-smokers has been
recognized as a different clinical entity with a unique epide-
miologic and molecular profiles.2–5 Lung cancer patients who
are never-smokers are predominantly women with adenocar-
cinoma or bronchioloalveolar carcinoma (BAC) histologies
and with younger age at presentation.2–9 The current pub-
lished literature is not uniform on whether never-smoking
status confers a survival advantage9 even though the majority
of the reports do show that never-smoking status is a favor-
able prognostic for overall survival (OS) and lung cancer-
specific survival.5–8 In our epidemiologic studies of non-
small cell lung cancer (NSCLC) using the statewide
California Cancer Registry (CCR) database, we consistently
found that Asian ethnicity was an independent favorable
prognostic factor for survival by Cox proportional hazards
analysis in early stage,10 advanced stage,11 or NSCLC as a
whole.12 Given that never-smokers comprised a high propor-
tion of Asian NSCLC patients and that never-smokers tend to
have better survival than ever-smokers, we could not defin-
itively conclude the favorable prognostic significance of
Asian ethnicity without accounting for smoking status (which
was not available in the statewide CCR database). Previously,
we had successfully abstracted smoking data from the re-
gional CCR using a text-mining program.13 In this report,
we investigated whether the prognostic significance of
Asian ethnicity is independent of smoking status by ab-
stracting smoking status of NSCLC patients from Orange,
San Diego, and Imperial counties in Southern California.
We further investigated the epidemiologic and survival
characteristics of never-smokers with NSCLC from these
three counties.
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MATERIALS AND METHODS
Population
This was a retrospective study involving analysis of
data from the Cancer Surveillance Programs of Orange,
Imperial, and San Diego counties (CSPOC/SANDIOCC da-
tabases) in the state of California (area population of 6
million). NSCLC patients diagnosed between 1991 and 2005
with complete follow-up data were included in the study.
Tumor site and histology were abstracted as described pre-
viously.13 The histology category of mixed/carcinoma not
otherwise specified (NOS)/other was obtained by examining
histologic codes that did not further classify NSCLC into
adenocarcinoma, squamous cell, large cell, or BAC. Ameri-
can Joint Committee on Cancer (AJCC) stages were deter-
mined from programming according to the sixth edition
AJCC staging system using available clinical and pathologic
tumor, node, metastasis data from the cancer registry. Patient
demographic data including ethnicity, gender, surgical tech-
niques, radiation, and chemotherapy given during the first
course of therapy and clinicopathologic data such as his-
tologic differentiation were abstracted using Surveillance,
Epidemiology, and End Results codes. The measurement
of socioeconomic status (SES) and marital status used in
this analysis was a composite measure using CCR and
census data as described previously.14
Smoking status was abstracted by examining individual
patient text file using a customized text-mining program.14
Patients with any documented history of smoking were clas-
sified as “ever-smokers.” Patients with documentation of no
smoking history were classified as “never-smokers.” Patients
lacking documented information on smoking history were
excluded from this analysis. The last date of follow-up was
either the date of death or the last date the patient was
contacted.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for NSCLC patients, using Pearson 2
statistic or Fisher exact test for nominal variables and Student
t test for continuous variables. Comparison of nonparametric
values across two groups was done using Wilcoxon rank sum
test. Univariate survival rate analyses were estimated using
the Kaplan and Meier method, with comparisons made be-
tween groups by the log-rank test. Cox proportional hazards
modeling using time since diagnosis were performed. All
statistical analyses were conducted using SAS 9.1 statistical
software (SAS Institute, Inc., Cary, NC). Statistical signifi-
cance was assumed for a two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (IRB #2007-
6078).
RESULTS
A total of 20,140 patients with known smoking status
were analyzed between 1991 and 2005. One thousand eight
hundred thirty-nine patients (9.1%) were never-smokers. The
median age of all patients was 69 years (95% confidence
level: 49–85). The median follow-up time for all patients was
8 months (range, 0–185). Eight thousand four hundred thirty-
four patients with unknown smoking status were excluded
from the analysis.
Period of Diagnosis
The proportion of NSCLC patients who were never-
smokers steadily increased from periods 1991 to 1995, 1996
to 2000, and 2001 to 2005 (7.8%, 8.8%, and 11.0% respec-
tively, ptrend  0.0001). The increase in proportion of never-
smokers was significant for both male (ptrend  0.0018) and
female (ptrend  0.0001) patients. The increase in proportion
of never-smokers was also significant for Asian (16.7%,
23.9%, and 29.1% respectively, ptrend  0.0001) and white
(ptrend  0.0006) but not for African American (ptrend 
0.2824) or Hispanic (ptrend  0.2285) patients. The percent-
ages of never-smokers among NSCLC patients and for Asian
NSCLC patients according to a period of diagnosis were
plotted in Figure 1.
Analysis by Smoking Status
Age at Diagnosis
The median age at diagnosis for smokers was 69 years
compared with 72 years for never-smokers (p  0.0001;
Wilcoxon two-sample test) (Table 1). Nevertheless, the per-
centage of all never-smokers younger than 50 years was
higher than all ever-smokers (9.9% versus 5.2%), for male
never-smokers than male ever-smokers (10.3% versus 5.4%),
and for female never-smokers versus female ever-smokers
(9.7% versus 5.0%).
Gender
A greater proportion of never-smokers were women
(65.6%) compared with ever-smokers (43.0% female) (p 
0.0001) (Table 1).
Ethnicity
Five Asian subgroups (Filipino, Vietnamese, Japanese,
Chinese, and Korean) were made up of the majority (86.1%)
of the Asian population. There was about a threefold increase
in the percentage of Asians who were never-smokers as
compared with ever-smokers. Among female NSCLC pa-
tients, there was a twofold increase in Hispanic patients who
were never-smokers as compared with ever-smokers and
about a sixfold increase in Asian who were never-smokers as
compared with ever-smokers.
Histology
There was about a threefold increase in the percentage
of BAC among never-smokers (10.6%) compared with ever-
smokers (3.3%) whereas there was a corresponding 50%
reduction of the percentages of squamous cell carcinoma
among ever-smokers (24.6%) compared with never-smokers
(10.8%). Adenocarcinoma constituted a greater proportion of
histology type from among never-smokers (50.6%) than ever-
smokers (39.5%).
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Histologic Differentiation
There was more than twofold increase in the proportion
of well-differentiated tumor among never-smokers (9.0%)
than ever-smokers (4.0%).
Stage
Slightly more than half of the never-smokers presented
with stage 4 disease (50.7%), which was higher than the
percentage of stage 4 disease among ever-smokers (45.3%).
Analysis by Ethnicity
NSCLC patients who were never-smokers constituted a
much higher proportion of the total NSCLC patients among
Asian (24.5%) and Hispanic (14.2%) patients as compared
with white (7.6%) and African American (5.4%) patients
(Table 2).
Median Age of Diagnosis
White never-smokers had a significant older age of
diagnosis than white ever-smokers (74 years versus 70 years;
p  0.0001) and so were African American never-smokers
(70 years versus 62 years; p  0.0216). Hispanic never-
smokers were significantly younger at the time of diagnosis
than Hispanic ever-smokers (66 years versus 69 years, p 
0.0109). Asian never-smokers were younger than ever-smok-
ers (67 years versus 68 years; p  0.1920) though the
difference was not statistically significant.
Gender
Female predominance of never-smokers were evident
across all four ethnicities from 62.8% of white, 71.8% of
Asian, 72.1% of Hispanic, and 72.7% of African American
patients (Table 2). In addition, 48.5% of Asian and 25.8% of
Hispanic female NSCLC patients were never-smokers as
compared with 10.3% of white and 9.8% of African Ameri-
can female NSCLC patients who were never-smokers (Table 3).
Univariate Survival Analysis
Smoking Status
The 1-year, 2-year, 3-year, 5-year survival estimates
and median OS for NSCLC patients who were never-smokers
(43.7%, 32.7%, 22.7%, 16.1%, and 11 months, respectively)
were significantly better when compared with the survival
estimates for ever-smokers (40.0%, 26.1%, 19.9%, 14.2%,
and 8 months, respectively; p  0.0183) (Figure 2).
Stage
The 1-year, 5-year survival estimates, and median
OS for AJCC stage 1 patients were 81.9%, 47.9%, and 55
months, respectively. The corresponding values were
70.3%, 25.8%, and 24 months, respectively, for stage 2
patients; 39.7%, 8.6%, and 9 months, respectively, for
stage 3 patients; and 21.6%, 3.4%, and 4 months, respec-
tively, for stage 4. The difference in survival among the 4
stages was statistically significant (p  0.0001). The
survival of patients with unknown stage was intermediate
between stage 2 and 3 patients (45.3%, 15.3%, and 11
months, respectively).
Histology
BAC had the most significant and best survival with
1-year, 5- year survival estimates and median OS of 73.3%,
42.7%, and 44 months, respectively. The corresponding val-
ues for squamous cell carcinoma were 45.7%, 15.7%, and 11
months, respectively, for large cell carcinoma; 43.0%, 16.3%,
and 9 months, respectively, for adenocarcinoma; 31.7%,
11.6%, and 6 months, respectively; and 28.0%, 6.1%, and 5
months, respectively, for mixed/NOS/other histology. The
survival difference was statistically different among adeno-
carcinoma, squamous cell carcinoma, large cell carcinoma,
and mixed/NOS/other histologies (p  0.0001).
FIGURE 1. Percentages of never-
smokers according to periods of
diagnosis (1991–1995, 1996–2000,
and 2001–2005).
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TABLE 1. Patient Characteristics (Total, Male, and Female) Stratified by Smoking Status
Total Male Female
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
n (%) 18,301 (90.9) 1839 (9.1) 10,431 (94.3) 632 (5.7) 7870 (86.7) 1207 (13.3)
Median age (yr) (95% CI) 69 (49–84) 72 (44–88) 0.0001a 69 (49–84) 71 (43–88) 0.0033a 70 (49–85) 72 (44–88) 0.0001a
Median follow-up time (mo) (range) 8 (0–185) 9 (0–181) 0.2048a 7 (0–184) 7 (0–181) 0.3088a 9 (0–185) 10 (0–1790 0.5364a
Period of diagnosis
1991–1995 6319 (34.5) 533 (29.0) 3734 (35.8) 193 (30.5) 2585 (32.9) 340 (28.2)
1996–2000 6202 (33.9) 595 (32.4) 3472 (33.3) 211 (33.4) 2730 (34.7) 384 (31.8)
2001–2005 5780 (31.6) 711 (38.7) 0.0001 3225 (30.9) 228 (36.1) 0.0077 2555 (32.5) 483 (40.0) 0.0001
Age
0–39 114 (0.6) 51 (2.8) 67 (0.6) 20 (3.2) 47 (0.6) 31 (2.6)
40–49 842 (4.6) 131 (7.1) 495 (4.8) 45 (7.1) 347 (4.4) 86 (7.1)
50–59 2735 (14.9) 255 (13.9) 1608 (15.4) 93 (14.7) 1127 (14.3) 162 (13.4)
60–69 5611 (30.7) 359 (19.5) 3341 (32.0) 132 (20.9) 2270 (28.8) 227 (18.8)
70–79 6341 (34.7) 568 (30.9) 3512 (33.7) 198 (31.3) 2829 (36.0) 370 (30.7)
80 2658 (14.5) 475 (25.8) 0.0001 1408 (13.5) 144 (22.8) 0.0001 1250 (15.9) 331 (27.4) 0.0001
Sex
Male 10431 (57.0) 632 (34.4) — — — —
Female 7870 (43.0) 1207 (65.6) 0.0001 — — — —
Ethnicity
White 15,418 (84.2) 1270 (69.1) 8465 (81.2) 472 (74.7) 6953 (88.3) 798 (66.1)
Asian 985 (5.4) 319 (17.3) 742 (7.1) 90 (14.2) 243 (3.1) 229 (19.0)
Hispanic 1298 (7.1) 215 (11.7) 851 (8.2) 60 (9.5) 447 (5.7) 155 (12.8)
African-American 578 (3.2) 33 (1.8) 357 (3.4) 9 (1.4) 221 (2.8) 24 (2.0)
Other/unknown 22 (0.1) 2 (0.1) 0.0001 16 (0.2) 1 (0.2) 0.0001 6 (0.08) 1 (0.1) 0.0001
Socioeconomic status
SES1 (lowest) 1585 (8.7) 156 (8.5) 1006 (9.6) 53 (8.4) 579 (7.4) 103 (8.5)
SES2 3098 (16.9) 266 (14.5) 1793 (17.2) 83 (13.1) 1305 (16.6) 183 (15.2)
SES3 3949 (21.6) 375 (20.4) 2277 (21.8) 115 (18.2) 1672 (21.2) 260 (21.5)
SES4 4972 (27.2) 476 (25.9) 2782 (26.7) 166 (26.3) 2190 (27.8) 310 (25.7)
SES5 (highest) 4509 (24.6) 529 (28.8) 2448 (23.5) 200 (31.6) 2061 (26.2) 329 (27.3)
Unknown 188 (1.0) 37 (2.0) 0.0006 125 (1.2) 15 (2.4) 0.0001 63 (0.8) 22 (1.8) 0.2496
Marital status
Married 10,231 (55.9) 1060 (57.6) 6965 (66.8) 458 (72.5) 3266 (41.5) 602 (49.9)
Unmarried 7700 (42.1) 750 (40.8) 3283 (31.5) 165 (26.1) 4417 (56.1) 585 (48.5)
Unknown 370 (2.0) 29 (1.6) 0.1988 183 (1.8) 9 (1.4) 0.0125 187 (2.4) 20 (1.7) 0.0001
Histology
Adenocarcinoma 7220 (39.5) 930 (50.6) 3885 (37.2) 301 (47.6) 3335 (42.4) 629 (52.1)
BAC 611 (3.3) 194 (10.6) 272 (2.6) 46 (7.3) 339 (4.3) 148 (12.3)
Large cell 1341 (7.3) 105 (5.7) 755 (7.2) 39 (6.2) 586 (7.5) 66 (5.5)
Squamous cell 4510 (24.6) 199 (10.8) 2900 (27.8) 96 (15.2) 1610 (20.5) 103 (8.5)
Mixed/NOS/Other 4619 (25.2) 411 (22.4) 0.0001 2619 (25.1) 150 (23.7) .0001 2000 (25.4) 261 (21.6) 0.0001
Histologic differentiation
Well differentiated 731 (4.0) 165 (9.0) 354 (3.5) 45 (7.1) 367 (4.7) 120 (9.9)
Moderately differentiated 2719 (14.9) 284 (15.4) 1504 (14.4) 81 (12.8) 1215 (15.4) 203 (16.8)
Poorly differentiated 6334 (34.6) 458 (24.9) 3632 (34.8) 185 (29.3) 2702 (34.3) 273 (22.6)
Undifferentiated 1040 (5.7) 62 (3.4) 623 (6.0) 19 (3.0) 417 (5.3) 43 (3.6)
Unknown 7477 (40.9) 870 (47.3) 0.0001 4308 (41.3) 302 (47.8) 0.0001 3169 (40.3) 568 (47.1) 0.0001
AJCC stage
Stage 0 4 (0.02) 0 (0.0) 2 (0.02) 0 (0.0) 2 (0.03) 0 (0.0)
Stage 1 2914 (15.9) 247 (13.4) 1491 (14.3) 66 (10.4) 1423 (18.1) 181 (15.0)
Stage 2 859 (4.7) 64 (3.5) 483 (4.6) 17 (2.7) 376 (4.8) 47 (3.9)
Stage 3 3497 (19.1) 271 (14.7) 2071 (19.9) 94 (14.9) 1426 (18.1) 177 (14.7)
Stage 4 8292 (45.3) 933 (50.7) 4883 (46.8) 360 (57.0) 3409 (43.3) 573 (47.5)
Unknown 2735 (14.9) 324 (17.6) 0.0001 1501 (14.4) 95 (15.0) 0.0001 1234 (15.7) 229 (19.0) 0.0001
Surgery
Yes 4932 (27.0) 452 (24.6) 2601 (24.9) 134 (21.2) 2331 (29.6) 318 (26.4)
No 13345 (72.9) 1382 (75.2) 7811 (74.9) 497 (78.6) 5534 (70.3) 885 (73.3)
Unknown 24 (0.1) 5 (0.3) 0.0310 19 (0.2) 1 (0.2) 0.1055 5 (0.1) 4 (0.3) 0.0017
(Continued)
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Histologic Differentiation
Well-differentiated histologic grade had the best
1-year, 5-year survival estimates, and median OS (71.8%,
42.1%, and 41 months, respectively) followed by moderately-
differentiated tumor (62.8%, 29.1%, and 22 months, respec-
tively), poorly-differentiated tumor (42.2%, 15.3%, and 9
months, respectively), and undifferentiated tumor (33.0%,
11.8%, and 6 months, respectively). Tumor with unknown
differentiation had the worst survival (28.2%, 5.6%, and 5
months, respectively). The survival difference was statisti-
cally significant (p  0.0001).
Ethnicity
Asian had the best survival among the four ethnicities
with 1-year, 5-year survival estimates, and median OS of
43.1%, 13.9%, and 10 months, respectively. The correspond-
ing values for white were 40.5%, 14.7%, and 9 months,
respectively; 39.7%, 13.8%, and 8 months, respectively, for
African Americans; and 35.6%, 11.3%, and 7 months, respec-
tively, for Hispanics. The survival difference was statistically
significant (p  0.0001). We also compared survival of
Asians to non-Asians according to AJCC stage. The 1-year,
5-year survival estimates and median OS of stage 1 Asians
(86.6%, 53.0%, and 67 months, respectively) were numeri-
cally improved and close to statistical significance when
compared with stage 1 non-Asians (81.6%, 47.7%, and 54
months, respectively; p  0.0614) (Figure 3A). For stage 2
patients, the 1-year, 5-year survival estimates, and median OS
of Asians(77.8%, 24.0%, 27 months, respectively) were again
numerically improved when compared with non-Asians
(69.9%, 25.9%, and 24 months, respectively; p  0.6106)
(Figure 3B). For stage 3 patients, the 1-year, 5-year survival
estimates, and median OS of Asians (46.4%, 11.0%, and 12
months, respectively) were significantly improved when
compared with non-Asians (39.2%, 8.4%, and 9 months,
respectively; p  0.0136) (Figure 3C). For stage 4 patients,
the 1-year, 5-year survival estimates, and median OS of
Asians (27.7%, 5.0%, and 6 months, respectively) were again
significantly improved when compared with non-Asians
(21.1%, 3.3%, and 4 months, respectively; p  0.0001)
(Figure 3D).
Gender
Female patients had significant improved 1-year, 5-year
survival estimates, and median OS (44.4%, 17.4%, and 10
months, respectively) as compared with male patients
(37.0%, 12.0%, and 7 months, respectively, p  0.0001).
Socioeconomic Status
There was significant improvement in 1-year, 5-year
survival estimates, and median OS with increasing SES. The
1-year, 5-year survival estimates, and median OS for the 5
SES quintiles were 36.3%, 11.5%, and 7 months, respec-
tively, for SES1; 35.7%, 11.7%, and 7 months, respectively,
for SES2; 38.7%, 13.3%, and 8 months, respectively, for
SES3; 41.0%, 15.2%, and 9 months, respectively, for SES4;
and 44.7%, 17.1%, and 10 months, respectively, for SES5
(p  0.0001).
Marital Status
Married patients had significant improved 1-year,
5-year survival estimates, and median OS (42.7%, 15.8%,
and 9 months, respectively) as compared with unmarried
patients (37.3%, 12.6%, and 7 months, respectively, p 
0.0001).
Treatment
Among patients with stage 1 disease, surgery conferred
significant survival advantage for both never-smokers (me-
dian OS: surgery versus no surgery, 89 months versus 17
months, p  0.0001) and ever-smokers (median OS: surgery
versus no surgery, 76 months versus 14 months, p  0.0001)
and for all four ethnicities (white: 76 months versus 14
months, p  0.0001; Hispanic: 65 months versus 17 months,
p 0.0001; Asian: 99 months versus 18 months, p 0.0001;
and African American: 100 months versus 15.5 months, p 
0.0007). Similarly, radiation conferred significant survival
advantage in stage 3 disease for both never-smokers (median
OS: radiation versus no radiation, 14 months versus 8
months, p 0.0001) and ever-smokers (median OS: radiation
versus no radiation, 11 months versus 5 months, p  0.0001)
and among all four ethnicities (white: 11 months versus 5
months, p  0.0001; Hispanic: 11 months versus 6 months,
p  0.0013; Asian: 14 months versus 7 months, p  0.0850;
TABLE 1. (Continued)
Total Male Female
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
Radiation
Yes 7958 (43.5) 655 (35.6) 4799 (46.0) 238 (37.7) 3159 (40.1) 417 (34.6)
No 10339 (56.5) 1184 (64.4) 5629 (54.0) 394 (62.3) 4710 (59.9) 790 (65.4)
Unknown 4 (0.02) 0 (0.0) 0.0001 3 (0.03) 0 (0.0) 0.0002 1 (0.01) 0 (0.0) 0.0010
Chemotherapy
Yes 5325 (29.1) 624 (33.9) 3160 (30.3) 228 (36.1) 2165 (27.5) 396 (32.8)
No 12923 (70.6) 1212 (65.9) 7240 (69.4) 404 (63.9) 5683 (72.2) 808 (66.9)
Unknown 53 (0.3) 3 (0.2) 0.0001 31 (0.3) 0 (0.0) 0.0041 22 (0.3) 3 (0.3) 0.0007
a p value calculated by Wilson two-sample test.
NOS, not otherwise specified; CI, confidence interval; SES, socioeconomic status; BAC, bronchioloalveolar carcinoma; AJCC, American Joint Committee on Cancer.
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TABLE 2. Patient Characteristics by Ethnicity and Stratified by Smoking Status
Caucasian (n  16,688) Hispanic (n  1513) Asian (n  1304) African-American (n  611)
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
Ever-
Smoker
Never-
Smoker p
n (%)a 15,418 (92.4) 1270 (7.6) 1298 (85.8) 215 (14.2) 985 (75.5) 319 (24.5) 578 (4.6) 33 (5.4)
Median age (yr) (95% CI) 70 (50–85) 74 (46–89) 0.0001b 69 (46–85) 66 (40–85) 0.0109b 68 (46–83) 67 (41–86) 0.1920b 62 (43–81) 70 (39–88) 0.0216b
Median follow-up time
(mo) (range)
8 (0–185) 9 (0–178) 0.5511b 6 (0–184) 8 (0–168) 0.0770b 8 (0–170) 10 (0–181) 0.2277b 7 (0–161) 4 (0–109) 0.4016b
Period of diagnosis
1991–1995 5519 (35.8) 421 (33.2) 378 (29.1) 48 (22.3) 245 (24.9) 49 (15.4) 168 (29.1) 14 (42.4)
1996–2000 5223 (33.9) 394 (31.0) 418 (32.2 83 (38.6) 351 (35.6) 110 (34.5) 205 (35.5) 8 (24.2)
2001–2005 4676 (30.3) 455 (35.8) 0.0002 502 (38.7) 84 (39.1) 0.0701 389 (39.5) 160 (50.2) 0.0003 205 (5.5) 11 (33.3) 0.2189
Age
0–39 72 (0.5) 24 (1.9) 18 (1.4) 10 (4.7) 12 (1.2) 15 (4.7) 12 (2.1) 2 (6.1)
40–49 622 (4.0) 73 (5.8) 82 (6.3) 26 (12.1) 64 (6.5) 28 (8.8) 74 (12.8) 4 (12.1)
50–59 2208 (14.2) 153 (12.1) 193 (14.9) 40 (18.6) 172 (17.5) 58 (18.2) 151 (26.1) 4 (12.1)
60–69 4717 (30.6) 218 (17.2) 394 (30.4) 51 (23.7) 300 (30.5) 85 (26.7) 193 (33.4) 5 (15.2)
70–79 4352 (35.4) 417 (32.8) 441 (34.0) 58 (27.0) 339 (34.4) 81 (25.4) 106 (18.3) 11 (33.3)
80 2347 (15.2) 385 (30.3) 0.0001 170 (13.1) 30 (14.0) 0.0001 98 (10.0) 52 (16.3) 0.0001 42 (7.3) 7 (21.2) 0.0019
Sex
Male 8465 (54.9) 472 (37.2) 851 (65.6) 60 (27.9) 742 (75.3) 90 (28.2) 357 (61.8) 9 (27.3)
Female 6953 (45.1) 798 (62.8) 0.0001 447 (34.4) 155 (72.1) 0.0001 243 (24.7) 229 (71.8) 0.0001 221 (38.2) 24 (72.7) 0.0001
Socioeconomic status
SES1 (lowest) 896 (5.8) 45 (3.5) 365 (28.1) 67 (31.2) 122 (12.4) 34 (10.7) 197 (34.1) 10 (30.3)
SES2 2449 (15.9) 150 (11.8) 280 (21.6) 48 (22.3) 214 (21.7) 63 (19.7) 150 (26.0) 5 (15.2)
SES3 3331 (21.6) 253 (19.9) 254 (19.6) 44 (20.5) 241 (24.5) 71 (22.3) 118 (20.4) 6 (18.2)
SES4 4438 (28.8) 373 (29.4) 243 (18.7) 24 (11.2) 216 (21.9) 73 (22.9) 71 (12.3) 6 (18.2)
SES5 (highest) 4147 (26.9) 424 (33.4) 146 (11.2) 29 (13.5) 176 (17.9) 69 (21.6) 39 (6.7) 6 (18.2)
Unknown 157 (1.0) 25 (2.0) 0.0001 10 (0.8) 3 (1.4) 0.1108 14 (1.4) 9 (2.8) 0.4876 3 (0.5) 0 (0.0) 0.0912
Marital status
Married 8553 (55.5) 712 (56.1) 750 (57.8) 121 (56.3) 724 (73.5) 213 (66.8) 195 (33.7) 14 (42.4)
Unmarried 6573 (42.6) 542 (42.7) 516 (39.8) 88 (40.9) 236 (24.0) 99 (31.0) 364 (63.0) 19 (57.6)
Unknown 292 (1.9) 16 (1.3) 0.2685 32 (2.5) 6 (2.8) 0.8985 25 (2.5) 7 (2.2) 0.0422 19 (3.3) 0 (0.0) 0.3831
Histology
Adenocarcinoma 6069 (39.4) 613 (48.3) 520 (40.1) 111 (51.6) 406 (41.2) 189 (59.3) 221 (38.2) 17 (51.5)
BAC 522 (3.4) 138 (10.9) 40 (3.1) 23 (10.7) 32 (3.3) 29 (9.1) 16 (2.8) 4 (12.1)
Large cell 1092 (7.1) 71 (5.6) 132 (10.2) 15 (7.0) 64 (6.5) 17 (5.3) 53 (9.2) 2 (6.1)
Squamous cell 3840 (24.9) 157 (12.4) 283 (21.8) 18 (8.4) 235 (23.9) 23 (7.2) 144 (24.9) 1 (3.0)
Mixed/NOS/other 3895 (25.3) 291 (22.9) 0.0001 323 (24.9) 48 (22.3) 0.0001 248 (25.2) 61 (19.1) 0.0001 144 (24.9) 9 (27.3) 0.0025
Histologic differentiation
Well 638 (4.1) 120 (9.5) 41 (3.2) 20 (9.3) 31 (3.2) 23 (7.2) 21 (3.6) 2 (6.1)
Moderately 2329 (15.1) 191 (15.0) 168 (12.) 37 (17.2) 137 (13.9) 53 (16.6) 82 (14.2) 3 (9.1)
Poorly 5382 (34.9) 325 (25.6) 441 (34.0) 43 (30.0) 331 (33.6) 84 (26.3) 177 (30.6) 4 (12.1)
Undifferentiated 856 (5.6) 49 (3.9) 95 (7.3) 8 (3.7) 49 (5.0) 4 (1.3) 38 (6.6) 1 (3.0)
Unknown 6213 (40.3) 585 (46.1) 0.0001 552 (42.6) 107 (49.8) 0.0001 437 (44.4) 155 (48.6) 0.0001 260 (45.0) 23 (69.7) 0.0516
AJCC stage
Stage 0 4 (0.02) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stage 1 2599 (16.9) 193 (15.2) 140 (10.8) 18 (8.4) 97 (9.9) 34 (10.7) 76 (13.2) 2 (6.1)
Stage 2 755 (4.9) 55 (4.3) 38 (2.9) 4 (1.9) 41 (4.2) 5 (1.6) 24 (4.2) 0 (0.0)
Stage 3 2922 (19.0) 193 (15.2) 230 (17.7) 26 (12.1) 231 (23.5) 47 (14.7) 108 (18.7) 5 (15.2)
Stage 4 6824 (44.3) 587 (46.2) 690 (53.2) 134 (62.3) 475 (48.2) 191 (59.9) 293 (50.7) 19 (57.6)
Unknown 2314 (15.0) 242 (19.1) 0.0001 200 (15.4) 33 (15.4) 0.0886 141 (14.3) 42 (13.2) 0.0005 77 (13.3) 7 (21.2) 0.3410
Surgery
Yes 4306 (27.9) 340 (26.8) 265 (20.4) 38 (17.7) 209 (21.2) 69 (21.6) 149 (25.8) 5 (15.2)
No 11,094 (72.0) 926 (72.9) 1028 (79.2) 176 (81.9) 776 (78.8) 250 (78.4) 428 (74.1) 28 (84.9)
Unknown 18 (0.1) 4 (0.3) 0.1218 5 (0.4) 1 (0.5) 0.6420 0 (0.0) 0 (0.0) 0.8760 1 (0.2) 0 (0.0) 0.3784
Radiation
Yes 6682 (43.3) 450 (35.4) 563 (43.4) 79 (36.7) 433 (44.0) 113 (35.4) 268 (46.4) 13 (39.4)
No 8732 (56.6) 820 (64.6) 735 (56.6) 136 (63.3) 552 (56.0) 206 (64.6) 310 (53.6) 20 (60.6)
Unknown 4 (0.03) 0 (0.0) 0.0001 0 (0.0) 0 (0.0) 0.0685 0 (0.0) 0 (0.0) 0.0072 0 (0.0) 0 (0.0) 0.4344
Chemotherapy
Yes 4375 (28.4) 394 (31.0) 404 (31.1) 78 (36.3) 355 (36.0) 137 (43.0) 183 (31.7) 14 (42.4)
No 11,001 (71.4) 874 (68.8) 887 (68.3) 136 (63.3) 627 (63.7) 182 (57.1) 394 (68.2) 19 (57.6)
Unknown 42 (0.3) 2 (0.2) 0.1041 7 (0.5) 1 (0.5) 0.3228 3 (0.3) 0 (0.0) 0.0575 1 (0.2) 0 (0.0) 0.4281
a Percentage calculated across the row.
b p value calculated by Wilson two-sample test.
NOS, not otherwise specified; CI, confidence interval; SES, socioeconomic status; BAC, bronchioloalveolar carcinoma; AJCC, American Joint Committee on Cancer.
Ou et al. Journal of Thoracic Oncology • Volume 4, Number 9, September 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer1088
and African American: 13 months versus 4 months, p 
0.0001). For stage 4 disease, chemotherapy also conferred
significant survival benefit for both never-smokers (median
OS; chemotherapy versus no chemotherapy, 10 months ver-
sus 3 months, p  0.0001) and ever-smokers (median OS:
chemotherapy versus no chemotherapy, 8 months versus 3
months, p  0.0001) and among all 4 ethnicities (white: 8
months versus 3 months; p  0.0001; Hispanic: 8 months
versus 3 months; p  0.0001; Asian: 9 months versus 3
months; p  0.0001; African American: 8 months versus 3
months: p  0.0001). Never-smokers derived an additional
2-month survival benefit as compared with ever-smokers
from chemotherapy. Similarly, Asians derived an additional
month survival benefit as compared with the other three
ethnicities from chemotherapy.
Asian Ethnicity by Smoking Status
Finally, we analyzed survival of Asians according to
smoking status. The 1-year, 5-year survival estimates, and
median OS of never-smokers (46.0%, 16.2%, and 11 months,
respectively) were numerically improved when compared
with never-smokers (42.2%, 13.2%, and 9 months, respec-
tively; p  0.1001) (Figure 4).
Multivariate Survival Analysis
Asian ethnicity (versus non-Asian; hazard ratio [HR]
0.861, 95% confidence interval [CI]: 0.808–0.918, p 
0.0001) was an independent and favorable prognostic factor
for OS after adjusting for age, gender, smoking status, AJCC
stage, histology, histologic differentiation, period of diagno-
sis, SES, marital status, surgery, radiation, and chemotherapy
(Table 4). Other independent favorable prognostic factors
were younger age at diagnosis, female gender, early stage of
diagnosis, BAC and squamous cell carcinoma histologies,
well-differentiated tumor, high SES, being married, diag-
nosed within the most recent period of diagnosis (2001–
2005), and treatment (surgery, radiation, and chemotherapy).
Never-smoker was no longer an independent prognostic fac-
tor after accounting for ethnicity (Table 4).
Asian ethnicity remained a favorable prognostic factor
for OS among never-smokers (versus non-Asian; HR 
0.841, 95% CI: 0.728–0.971, p  0.0180) and among ever-
smokers (versus non-Asian; HR  0.867, 95% CI: 0.807–
0.931, p  0.0001) (Table 5).
DISCUSSION
In this study, we demonstrated Asian ethnicity had
improved OS in NSCLC when compared with non-Asian
ethnicities by a univariate analysis, and Asian ethnicity is an
independent favorable prognostic factor for OS in NSCLC by
a multivariate analysis after accounting for smoking status
and other prognostic factors. It is well established that there
is a preponderance of never-smokers among Asian NSCLC
patients.2–4 Never-smokers harbor a high percentage of epi-
dermal growth factor receptor (EGFR) mutations and have
improved survival outcome. Thus, to investigate the prognos-
tic significance of Asian ethnicity, we abstracted smoking
status on 20,140 NSCLC patients to analyze the contribution
of smoking status into the Cox model. This allowed us to
study the epidemiologic difference between never-smokers
and ever-smokers NSCLC patients by gender and ethnicity.
We observed the well-characterized features of never-smok-
ers such as female preponderance, increased Asian represen-
tation, more adenocarcinoma and BAC, more well-differen-
tiated tumor, more stage 4 disease at presentation, improved
treatment survival, and improved survival outcome when
compared with ever-smokers. We observed that from 1991 to
2005 there was a statistical significant increase in the propor-
tion of NSCLC patients who were never-smokers, especially
among Asian women (Figure 1). In addition, female Asian
NSCLC patients had the highest percentage of never-smokers
(48.5%) followed by female Hispanic patients (25.8%) (Table
3). Our results are consistent with a report15 of a higher
incidence of female never-smokers with NSCLC from Cali-
TABLE 3. Breakdown of Smoking Status by Gender and
Ethnicity
Ever-
Smoker (%)a
Never-
Smoker (%)a
White
All (n  16,688) 15,418 (92.4) 1270 (7.6)
Male (n  8937) 8465 (94.7) 472 (5.3)
Female (n  7751) 6953 (89.7) 798 (10.3)
African American
All (n  611) 578 (94.6) 33 (5.4)
Male (n  366) 357 (97.5) 9 (2.5)
Female (n  245) 221 (90.2) 24 (9.8)
Asian
All (n  1304) 985 (75.5) 319 (24.5)
Male (n  832) 742 (89.2) 90 (10.8)
Female (n  472) 243 (51.5) 229 (48.5)
Hispanic
All (n  1513) 1298 (85.8) 215 (14.2)
Male (n  911) 851 (93.4) 60 (6.6)
Female (n  602) 447 (74.3) 155 (25.8)
a Percentage calculated across the row.
FIGURE 2. Kaplan–Meier survival curves of non-small cell
lung cancer (NSCLC) patients according to smoking status.
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fornia and Hawaii where large Asian and Hispanic popula-
tions reside. Of note, only 5.4% of African American NSCLC
patients were never-smokers. Consequently, NSCLC in Af-
rican Americans is a directly tobacco-related disease and
demonstrating the importance of smoking cessation efforts in
African Americans.
We also observed white6–9 and African American nev-
er-smokers had a higher median age of diagnosis whereas
Asian and Hispanic never-smokers had a lower median age of
diagnosis when compared with ever-smokers respectively.
Green et al reported 54.2% of Mexico-born NSCLC patients
aged 40 years and younger were never-smokers with an
increase in female-to-male ratio and proportion of adenocar-
cinoma.16 Differences in median age of diagnosis among
never-smokers from different ethnicities may indicate differ-
ent pathogenesis.
We demonstrated that Asians had significantly the best
OS by univariate analysis and that Asians had improved OS
when compared with non-Asians when stratified for stage.
Furthermore, among Asians, never-smokers had numeric im-
proved survival than ever-smokers. Our observation that
Asian ethnicity is a favorable prognostic factor is in agree-
ment with survival outcomes from recent clinical trials in
first-line17–19 and second line20–22 treatments of NSCLC in
which Asian patients had significantly better median OS than
FIGURE 3. A, Kaplan–Meier survival curves of stage 1 Asians versus non-Asians. B, Kaplan–Meier survival curves of stage 2
Asians versus non-Asians. C, Kaplan–Meier survival curves of stage 3 Asians versus non-Asians. D, Kaplan–Meier survival curves
of stage 4 Asians versus non-Asians.
FIGURE 4. Kaplan–Meier survival curves of Asians accord-
ing to smoking status.
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white patients independent of treatment assignment. In agree-
ment with our observation, Asian ethnicity was an independent
prognostic factor in BR-21 trial after factoring in smoking
status.22 Meta-analysis revealed a high level of EGFR protein
portends a poorer outcome in NSCLC.23 One mechanism that
modulates EGFR expression is polymorphism within the EGFR
gene. Interethnic polymorphism in the EGFR gene that tend to
result in lower EGFR expression are more common in Asians
compared with other ethnic groups.24,25 Polymorphism
in the EGFR gene has also been shown to affect survival in
NSCLC25,26 and may be one of the reasons why Asian ethnicity
is a favorable prognostic factor among never-smokers (Table 5).
TABLE 4. Cox Proportional Hazards Model for OS With or Without Ethnicity
Without Ethnicity With Ethnicity
HR 95% CI p HR 95% CI p
Smoking status
Ever-smoker 1.000 1.000
Never-smoker 0.936 0.886–0.988 0.0169 0.953 0.902–1.007 0.0861
Ethnicity
Non-Asian — 1.000
Asian — — — 0.861 0.808–0.918 0.0001
Gender
Male 1.000 1.000
Female 0.848 0.821–0.876 0.0001 0.845 0.818–0.872 0.0001
AJCC stagea
1 1.000 1.000
2 1.693 1.553–1.845 0.0001 1.694 1.554–1.846 0.0001
3 2.016 1.891–2.149 0.0001 2.024 1.899–2.157 0.0001
4 2.907 2.742–3.082 0.0001 2.913 2.747–3.088 0.0001
Age 1.010 1.009–1.012 0.0001 1.010 1.009–1.012 0.0001
Histology
Adenocarcinoma 1.000 1.000
BAC 0.783 0.711–0.862 0.0001 0.782 0.710–0.861 0.0001
Squamous cell carcinoma 0.937 0.901–0.976 0.0016 0.936 0.899–0.974 0.0013
Large cell carcinoma 1.001 0.933–1.075 0.9711 1.000 0.932–1.073 0.9981
Mixed/NOS/other 0.981 0.943–1.021 0.3446 0.980 0.942–1.020 0.3226
Histologic gradeb
Well differentiated 1.000 1.000
Moderately differentiated 1.248 1.135–1.372 0.0001 1.251 1.137–1.375 0.0001
Poorly differentiated 1.408 1.286–1.542 0.0001 1.410 1.287–1.543 0.0001
Undifferentiated 1.536 1.367–1.725 0.0001 1.536 1.367–1.725 0.0001
Period of diagnosis
1991–1995 1.000 1.000
1996–2000 0.971 0.937–1.006 0.1077 0.976 0.942–1.011 0.1782
2001–2005 0.907 0.872–0.944 0.0001 0.912 0.877–0.949 0.0001
Socioeconomic status 0.987 0.976–0.999 0.0363 0.986 0.974–0.998 0.0189
Marital statusb
Married 1.000 1.000
Unmarriedc 1.062 1.029–1.097 0.0002 1.056 1.022–1.091 0.0009
Surgeryb
No 1.000 1.000
Yes 0.328 0.312–0.346 0.0001 0.328 0.311–0.345 0.0001
Radiationb
No 1.000 1.000
Yes 0.845 0.818–0.874 0.0001 0.843 0.816–0.871 0.0001
Chemotherapyb
No 1.000 1.000
Yes 0.652 0.628–0.676 0.0001 0.652 0.628–0.677 0.0001
a Unknown stage included in the Cox proportional hazards analysis but not shown.
b Others included in the Cox proportional hazards model analysis but not shown.
c Unmarried  single, separated, divorced, and widowed.
OS, overall survival; HR, hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified.
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One of the major limitations of this study is that we
could not capture the degree of environmental tobacco smoke
(ETS) exposure. This limitation is not unique to our study as
other studies also were not able to quantify the amount of
ETS.5–9 Future investigations should try to capture ETS
exposure by detailed questionnaires in both cancer registry
and prospective trials and determine which genetic changes in
never-smokers with NSCLC are unique to geography and/or
ethnicity.
Never-smokers may have better performance status or
less comorbidity that we could not capture within the CCR.
We reassigned as many patients as possible to one of the 4
AJCC stages to allow more accurate and clinical relevant
analysis rather than using the Surveillance, Epidemiology,
and End Results summary staging of local, regional and
distant disease. Still AJCC stages were unknown in approx-
imately 15% of the patients. Nevertheless, these patients were
evenly distributed among ever-smokers and never-smokers,
and they were factored in the final Cox analysis. Other
limitations included no standardized staging or treatment
algorithm. The use of complimentary medicine was also not
recorded. Treatment decisions may have been confounded by
the physician-patient interaction. The differential benefit of
treatment in never-smokers over ever-smokers is retrospec-
tive though this observation is supported by recent prospec-
tive clinical trials.17,19,20
Epidemiologic2,3,5–9,27 and molecular profiling stud-
ies4,28–30 have clearly demonstrated that NSCLC in never-
smokers is distinct from NSCLC in ever-smokers. A recent
clinical trial demonstrated that NSCLC in never-smokers is a
heterogeneous disease even in a relatively homogeneous
Asian population where never-smokers can be broadly di-
vided into patients with EGFR wild-type and mutation-posi-
tive phenotypes with differential response to chemotherapy or
tyrosine kinase inhibitor depending on EGFR mutation sta-
tus.19 Furthermore, different EGFR mutations had different
clinical outcomes when treated with the EGFR-tyrosine ki-
nase inhibitor.31 Future large-scale collaborative epidemio-
logic and molecular profiling studies should be performed to
better characterize ethnic differences of NSCLC in never-
smokers and in ever-smokers.
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